Eli Lilly’s new, $1B pain drug racks up another promising round of PhIII pain data
Eli Lilly spent close to a billion dollars to get its hands on the migraine drug lasmiditan, bagging CoLucid in January as a way to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
